PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

Inclusion Criteria: * Age greater than or equal to 18 years * Participants must have histologically confirmed Stage III unresectable or Stage IV metastatic melanoma * Patients should be treatment naïve and eligible for treatment with anti-PD-1 or anti-PD-1/LAG3 as a first line therapy (as selected by their treating physician) * Patients previously treated for melanoma with surgical resection alone who present with recurrent Stage III unresectable or Stage IV metastatic melanoma are eligible for enrollment * Patients who were previously treated with systemic neo-adjuvant or adjuvant anti-PD-1 therapy more than 6 months prior to study enrollment will be eligible. There are no restrictions to the use of prior BRAF targeted therapy. * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral CT scan * Diagnostic imaging studies such as MRIs and CT scans must be performed within 30 days of the date of registration * Participants must have normal organ and marrow function as defined below: * Leukocytes (WBC) \> 3,000/uL * Absolute neutrophil count \> 1,500uL * Platelets \> 100,000/uL * Total bilirubin \< 1.5 X institutional upper limits of normal; total bilirubin \> 1.5X above institutional upper limits of normal will be allowed if direct bilirubin is within normal limits or if patients has a docume…